Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

Completed · Phase 4 · Has a placebo group

Conditions studied: Schizophrenia

In brief

A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia

Key facts

Study ID

NCT00080327

Run by

Otsuka Pharmaceutical Development & Commercialization, Inc.

People needed

370

Starts

2003-11-01

Expected to finish

2004-09-01

Last updated by the study team

2013-11-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women, ages 18 and older, with a worsening of schizophrenia symptoms over the past three months

Where it is running

• Bristol-Meyers Squibb Call Center — Wallingford, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.